The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...
the current widely prescribed type of medicine aimed at obesity and diabetes. Roche has been making the case that the obesity market is large enough for it to enter the field, if a bit later than ...
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results